Stockscreener 앱 받기
0.6376
5.12%
-0.0344
전일 마감가:
$0.672
열려 있는:
$0.6251
하루 거래량:
15.99M
Relative Volume:
39.87
시가총액:
$21.29M
수익:
$454.00K
순이익/손실:
$-21.72M
주가수익비율:
-1.1947
EPS:
-0.5337
순현금흐름:
$-25.74M
1주 성능:
-6.22%
1개월 성능:
-3.20%
6개월 성능:
+11.92%
1년 성능:
-53.80%
1일 변동 폭
$0.6123
$0.6581
1주일 범위
$0.6123
$0.6845
52주 변동 폭
$0.2805
$1.595
Vyne Therapeutics Inc Stock (VYNE) Company Profile
명칭
Vyne Therapeutics Inc
전화
800-775-7936
주소
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.6376 | 21.29M | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-31 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-11-18 | 개시 | BTIG Research | Buy |
| 2021-12-06 | 재개 | H.C. Wainwright | Buy |
Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스
VYNE Therapeutics Announces Special Cash Dividend in Connection With Pending Merger With Yarrow Bioscience - Moomoo
Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend? - Kalkine Media
Vyne Therapeutics Declares Special Cash Divid - Moomoo
VYNE Announces Special Cash Dividend Ahead of Merger - GuruFocus
VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026 - marketscreener.com
VYNE Therapeutics declares $16.5M dividend ahead of merger - Investing.com
VYNE Therapeutics Announces $16.5M Special Cash Dividend Ahead of Merger with Yarrow Bioscience - Minichart
VYNE declares special dividend ahead of Yarrow merger - TipRanks
VYNE Therapeutics declares $16.5M special cash dividend tied to Yarrow merger - TradingView
VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience - Quiver Quantitative
VYNE Therapeutics (NASDAQ: VYNE) declares $0.38/share special dividend tied to merger - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
VYNE stock holds its ground. Focus turns to the company profile. - ad-hoc-news.de
VYNEVYNE Therapeutics Inc Forecast, Target Price - Finviz
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
VYNE Therapeutics (VYNE) CSO reports 2,370-share tax withholding on RSU vesting - Stock Titan
VYNE Therapeutics (VYNE) CLO has shares withheld to cover RSU taxes - Stock Titan
VYNE (VYNE) CEO Domzalski has 12,214 shares withheld for RSU taxes - Stock Titan
Price to book forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Enterprise value to EBIT forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Price to earnings forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Price to sales forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
Enterprise value to EBITDA forward of VYNE Therapeutics Inc. – NASDAQ:VYNE - TradingView
VYNE Therapeutics Inc Actuals & Estimates (NASDAQ:VYNE) - TradingView
VYNE Therapeutics Inc Actuals & Estimates (BOATS:VYNE) - TradingView
Vyne Therapeutics Inc (VYNE) Institutional Confidence - TradingKey
VYNE Therapeutics StockSunday background on a micro-cap dermatology player - AD HOC NEWS
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[EFFECT] VYNE Therapeutics Inc. SEC Filing - Stock Titan
VYNE (VYNE) merger with Yarrow: $100M financing, 35.8441 exchange ratio - Stock Titan
Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE) - Stock Titan
VYNE Q1 2026 Earnings: EPS Beat Estimate, No Revenue ReportedFinancial Summary - newsline.com
VYNE Therapeutics (VYNE) Edges Higher in Quiet Trading, Testing Key Resistance at $0.69New Listing Stocks - newsline.com
VYNE Therapeutics (VYNE) Consolidates Near Support After Slight PullbackMACD Signal Stocks - newsline.com
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
VYNE Therapeutics (VYNE) Posts Modest Gain, Holds Above Key SupportMotive Wave - newsline.com
VYNE Therapeutics (VYNE) Edges Lower as Shares Test Key Support Near $0.65Standard Deviation - thelegaladvocate.com
RKTO Stock Price and Chart — NASDAQ:RKTO - TradingView
VYNE Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost DisciplineEarnings Preview - dars.gov.et
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline - TipRanks
VYNE to Advance YB-101 into Phase 2 in Q2 2026; $200M Raised, Phase 2a Readout Expected H2 2027 - TradingView
Yarrow reverse merger refocuses VYNE (NASDAQ: VYNE) with $200M war chest - Stock Titan
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04 - MSN
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vyne Therapeutics Inc (VYNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):